Adis Journals
UST-CD-BB-001 Plain language summary with DOI 17 Jun.pdf (192.43 kB)

AVT04: An Ustekinumab Biosimilar

Download (192.43 kB)
online resource
posted on 2024-06-16, 22:55 authored by Hannah A. Blair



Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest During the peer review process, Alvotech and STADA, the marketing authorization holders of AVT04, were offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit. Hannah Blair is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here



AVT04 (Uzpruvo®) is a biosimilar of the reference anti-interleukin (IL)-12 and IL-23 monoclonal antibody ustekinumab. It is approved in the EU for plaque psoriasis, paediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease as per the reference product. AVT04 has similar physicochemical characteristics to those of reference ustekinumab, and the pharmacokinetic similarity of the agents has been shown in healthy volunteers and patients with moderate to severe chronic plaque psoriasis. AVT04 demonstrated clinical efficacy similar to that of reference ustekinumab in patients with moderate to severe chronic plaque psoriasis, and was generally well tolerated in this population. The tolerability, safety and immunogenicity profiles of AVT04 were similar to those of reference ustekinumab, and switching from reference ustekinumab to AVT04 had no impact on efficacy, safety or immunogenicity. The role of reference ustekinumab in the management of inflammatory diseases is well established and AVT04 provides an effective biosimilar alternative for patients requiring ustekinumab therapy.

© Springer Nature Switzerland AG 2024


Usage metrics

    Clinical Drug Investigation



    Ref. manager